<DOC>
	<DOCNO>NCT00265642</DOCNO>
	<brief_summary>The purpose study examine efficacy irbesartan progression liver fibrosis adult patient chronic hepatitis C. The expected total enrollment 200 patient . Patients meet study criterion accept participate study take day one tablet 150 mg treatment ( irbesartan placebo ) two year . The assessment efficacy make evaluation area liver fibrosis blood marker liver fibrosis</brief_summary>
	<brief_title>Evaluation Irbesartan Hepatic Fibrosis Chronic Hepatitis C</brief_title>
	<detailed_description>The result several study suggest AT1 receptor antagonist angiotensin II inhibitory effect TGF-beta 1 production limit progression liver fibrosis . Therefore , angiotensin II could another mediator synthesis extra-cellular matrix hepatic level , open new perspective antagonist angiotensin II receptor drug ( ARA2/sartans ) . This study randomize , double blind , multi-center , parallel assignment , efficacy study .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Irbesartan</mesh_term>
	<criteria>age 18 75 year liver biopsy perform ( less 18 month inclusion ) , fibrosis score F2 , F3 F3+ Metavir classification , patient without antiviral therapy contraindication anti viral treatment non responder relapsers patient past antiviral treatment hepatocellular carcinoma HIV alcool abuser cirrhosis antifibrotic treatment pregnancy breast feeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>Hepatitis C , Chronic</keyword>
	<keyword>irbesartan</keyword>
</DOC>